XSTO
MAGLE
Market cap2mUSD
Jul 08, Last price
1.01SEK
1D
0.00%
1Q
-73.70%
IPO
-95.72%
Name
Magle Chemoswed Holding AB
Chart & Performance
P/E
—
P/S
0.07
EPS
—
Div Yield, %
34.65%
Shrs. gr., 5y
22.07%
Rev. gr., 5y
14.73%
Revenues
283m
+19.86%
Net income
-160m
L
CFO
-32m
L+172.93%
Dividend
Apr 26, 20240.35 SEK/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Magle Chemoswed Holding AB (publ), based in Malmö, Sweden, specializes in the research, development, and manufacturing of products within the pharmaceutical chemistry and technology sectors. The company's core activities include the process development and production of Active Pharmaceutical Ingredients (APIs), as well as the innovation and manufacturing of advanced wound care and diagnostic products, primarily leveraging its proprietary degradable starch microsphere technology. Its API portfolio features Warfarin sodium, used as an anticoagulant; Melperone hydrochloride, an antipsychotic agent; Isradipine, a calcium channel blocker for hypertension; Amantadine sulfate, for central nervous system disorders; and Benserazide hydrochloride, utilized with L-Dopa in Parkinson's disease treatment. Furthermore, Magle Chemoswed offers a range of medical devices for advanced wound care, surgical diagnostics, and drug delivery. These include EmboCept S, a microsphere-based device for vascular occlusion in liver and lung tumors; SmartGel, an innovative non-allergenic hydrogel derived from their microsphere platform; SmartPAN, a diagnostic tool for detecting pancreatic fluid leakage during surgical procedures; and EmboCept M, designed for managing benign prostatic hyperplasia. The company provides contract services to the pharmaceutical and medical device industries. Founded in 1944, Magle Chemoswed Holding AB (publ) operates as a subsidiary of Magle AB.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||